Preview

Epilepsy and paroxysmal conditions

Advanced search

Results of the expert forum on the use of perampanel in adolescents with epilepsy in everyday clinical practice

https://doi.org/10.17749/2077-8333/epi.par.con.2020.054

Full Text:

Abstract

In June 2020, an online forum of experts on the use of perampanel in adolescents with epilepsy in everyday clinical practice was held. The main goal was to discuss the features of juvenile epilepsy, its diagnosis, the possibilities of using perampanel in this category of patients, and the effectiveness of using the drug in everyday clinical practice. The forum was attended by leading experts in neurology and epileptology. Current data on the epidemiology of epilepsy in the child and juvenile population were presented; the issues of difficulties and diagnostic errors were considered, as well as features of managing adolescents with epilepsy, adverse events of antiepileptic therapy, results of studies on the effectiveness of perampanel, and many social aspects of the life of patients in this category.

About the Author

article Editorial

Russian Federation


References

1. Wheless J.W., Kim H.L. Adolescent seizures and epilepsy syndromes. Epilepsia. 2002; 43 (Suppl 3): 33–52. https://doi.org/10.1046/j.1528-1157.43.s.3.12.x.

2. Mukhin К.Yu., Petrukhin А.S. Idiopathic forms of epilepsy: taxonomy, diagnosis, and therapy. Мoscow: Art-Biznes-Tsentr; 2000: 176–88 (in Russ.).

3. Temkin O. The falling sickness: a history of epilepsy from the Greeks to the beginnings of modern neurology. Baltimore: Johns Hopkins Press; 1945. https://doi.org/10.1002/1097-4679(194607)2:3<301::AIDJCLP2270020319>3.0.CO;2-7.

4. Bandler B., Dykens J.W., Kaufman I.C., et al. Seizures and the menstrual cycle. Am J Psychiatry. 1957; 113 (8): 704–8. https://doi.org/10.1176/ajp.113.8.704.

5. Logothetis J., Harner R., Morrell F., Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology. 1959; 9 (5): 352–60. https://doi.org/10.1212/wnl.9.5.352.

6. Delgado-Escueta A.V., Medina M.T., Serratosa J.M., et al. Mapping and positional cloning of common idiopathic generalized epilepsies: juvenile myoclonic epilepsy and childhood absence epilepsy. Adv Neurol. 1999; 79: 351–74.

7. Reutens D.C., Berkovic S.F. Idiopathic generalized epilepsy of adolescence: are the syndrome sclinically distinct? Neurology. 1995; 45 (8): 1469–76. https://doi.org/10.1212/wnl.45.8.1469.

8. Janz D. The idiopathic generalized epilepsies of adolescence with childhood and juvenile age of onset. Epilepsia. 1997; 38 (1): 4–11. https://doi.org/10.1111/j.1528-1157.1997.tb01073.x.

9. Montalenti E., Imperiale D., Rovera A., et al. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci. 2001; 184 (1): 65–70. https://doi.org/10.1016/s0022-510x(00)00496-2.

10. Currie S., Heathfield K.W., Henson R.A., Scott D.F. Clinical course and prognosis of temporal lobe epilepsy. A survey of 666 patients. Brain. 1971; 94 (1): 173–90. https://doi.org/10.1093/brain/94.1.173.

11. Ramos-Lizana J., Cassinello-García E., Carrasco-Marina L., et al. Remission of epilepsy after onset of antiepileptic treatment: a prospective study in childhood. Rev Neurol. 2001; 33 (11): 1021–6 (in Spanish).

12. Kotsopoulos I.A., van Merode T., Kessels F.G., et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia. 2002; 43 (11): 1402–9. https://doi.org/10.1046/j.1528-1157.2002.t01-1-26901.x.

13. Cloyd J., Hauser W., Towne A., et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006; 68 (Suppl 1): S39–48. https://doi.org/10.1016/j.eplepsyres.2005.07.016.

14. Engel J., Pedley T.A. Epilepsy: a comprehensive textbook. 2nd ed. Lippincott Williams & Wilkins; 2008.

15. Annegers J.F., Hauser W.A., Lee J.R., Rocca W.A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia. 1995; 36 (4): 327–33. https://doi.org/10.1111/j.1528-1157.1995.tb01005.x.

16. Guzeva V.V. Clinical and epidemiological characteristics of epilepsy in children of the Leningrad region. In: Guzeva V.V., Guzeva О.V. (Eds.) Materials of the Student Scientific Conference. April 28–29, 2005. P. 1. Saint-Petersburg: SPb GPMA; 2005: 18–9 (in Russ.).

17. Fisher R.S., Acevedo C., Arzimanoglou A., et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014; 55 (4): 475–82. https://doi.org/10.1111/epi.12550.

18. Noachtar S., Carreno M., Foldvary N., Lüders H.O. Seizures and pseudoseizures. Suppl Clin Neurophysiol. 2000; 53: 259–70.

19. Uldall P., Alving J., Hansen L.K., et al. The misdiagnosis of epilepsy in children admitted to a tertiary epilepsy center with paroxysmal events. Arch Dis Child. 2006; 91 (3): 219–21. https://doi.org/10.1136/adc.2004.064477.

20. International League Against Epilepsy. Diagnostic manual. Epilepsy imitators. Available at: https://www.epilepsydiagnosis.org/epilepsyimitators.html (accessed December 23, 2020).

21. Aivazyan S.O. Non epileptic paroxysmal events imitating epilepsy in children. Epilepsy and Paroxysmal Conditions. 2016; 8 (4): 23–33 (in Russ.). https://doi.org/10.17749/2077-8333.2016.8.4.023-033.

22. Smith P.E. The teenager with epilepsy: has special needs. BMJ. 1998; 317 (7164): 960–1. https://doi.org/10.1136/bmj.317.7164.960.

23. Lerner R.M., Steinberg L. The scientific study of adolescent development. In: Lerner R.M., Steinberg L. (Eds.) Handbook of adolescent psychology. 3rd ed. Hoboken: Wiley; 2009.

24. Casey B.J., Jones R.M., Hare T.A. The adolescent brain. Ann N Y Acad Sci. 2008; 1124: 111–26. https://doi.org/10.1196/annals.1440.010.

25. Sørensen K., Mouritsen A., Aksglaede L., et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr. 2012; 77 (3): 137–45. https://doi.org/10.1159/000336325.

26. Lossius M.I., Alfstad K.Å., Van Roy B., et al. Early sexual debut in Norwegian youth with epilepsy: a population-based study. Epilepsy Behav. 2016; 56: 1–4. https://doi.org/10.1016/j.yebeh.2015.12.014.

27. Camfield P., Camfield C., Busiah K., et al. The transition from pediatric to adult care for youth with epilepsy: basic biological, sociological, and psychological issues. Epilepsy Behav. 2017; 69: 170–6. https://doi.org/10.1016/j.yebeh.2016.11.009.

28. Baker G., Spector S., McGrath Y., Soteriou H. Impact of epilepsy in adolescence: a UK controlled study. Epilepsy Behav. 2005; 6 (4): 556–62. https://doi.org/10.1016/j.yebeh.2005.03.011.

29. Asato M.R., Manjunath R., Sheth R.D., et al. Adolescent and caregiver experiences with epilepsy. J Child Neurol. 2009; 24 (5): 562–71. https://doi.org/10.1177/0883073809332396.

30. Camfield P.R., Andrade D., Camfield C.S., et al. How can transition to adult care be best orchestrated for adolescents with epilepsy? Epilepsy Behav. 2019; 93: 138–47. https://doi.org/10.1016/j.yebeh.2018.12.015.

31. Leppik I.E. Сompliance during treatment of epilepsy. Epilepsia. 1988; 29 (Suppl 2): S79–84. https://doi.org/10.1111/j.1528-1157.1988.tb05801.x.

32. Jin J., Sklar G.E., Oh M.N., Li S.C. Factors affecting therapeuticcompliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008; 4 (1): 269–86.

33. Bond W.S., Hussar D.A. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991; 48 (9): 1978–88.

34. Semenova О.N., Naumova Е.А. Factors influencing adherence to therapy: WHO parameters and opinion of patients in the cardiology department. Bulletin of Medical Internet Conferences. 2013; 3 (3): 507–11 (in Russ.).

35. Trostle J. Doctors’ orders and patients’ self–interest: two views of medication usage. In: Schmidt D., Leppik I.E. (Eds.) Compliance in epilepsy. NY: Elsevier Science Publishers BV (Biomedical Division); 1988: 57–69.

36. Mitchell W.G., Scheier L.M., Baker S.A. Adherence to treatment in children with epilepsy: who follows “doctor's orders”? Epilepsia. 2000; 41 (12): 1616–25. https://doi.org/10.1111/j.1499-1654.2000.001616.x.

37. Cramer J.A. The Titanic impact of medication compliance–adherence on epilepsy. Available at: https://www.epilepsy.com/article/2014/3/titanic-impact-medication-compliance-epilepsy (accessed December 23, 2020).

38. Buck D., Jacoby A., Baker G.A., Chadwick D.W. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997; 6 (2); 87–93. https://doi.org/10.1016/s1059-1311(97)80060-x.

39. Ermolenko N.А., Buchneva I.А. The choice of the initial antiepileptic therapy in adolescents. Epilepsiya.Medi.ru. 2013; 2 (10): 3–8 (in Russ.).

40. Kyngäs H. Predictors of good compliance in adolescents with epilepsy. Seizure. 2001; 10 (8); 549–53. https://doi.org/10.1053/seiz.2001.0557.

41. Faught E., Duh M.S., Weiner J.R., et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008; 71 (20): 1572–8. https://doi.org/10.1212/01.wnl.0000319693.10338.b9.

42. Paschal A.M., Hawley S.R., Romain T.S., Ablah E. Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions. Epilepsia. 2008; 49 (7): 1115–22. https://doi.org/10.1111/j.1528-1167.2008.01645.x.

43. Koychuev А.А. Adherence to treatment: assessment methods, technologies for correcting insufficient adherence to therapy. Medical News of North Caucasus. 2013; 8 (3): 65–9 (in Russ.).

44. Meador K.J., Yang H., Pina-Garza J.E., et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016; 57 (2): 243–51. https://doi.org/10.1111/epi.13279.

45. Piña-Garza J.E., Rosenfeld W., Saeki K., et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav. 2020; 104 (Pt A): 106876. https://doi.org/10.1016/j.yebeh.2019.106876.

46. Kim H.D., Chi C.S., Desudchit T., et al. Review of clinical studies of perampanel in adolescent patients. Brain Behav. 2016; 6 (9): e00505. https://doi.org/10.1002/brb3.505.

47. Nikanorova M., Olofsson K., Ehrenreich K., et al. Perampanel in children with focal epilepsy: which factors may influence its efficacy? Epilepsia. 2019; 60 (S2): 106–7.

48. Kim E.H., Ko T.S. Cognitive impairment in childhood onset epilepsy: up-to-date information about its causes. Korean J Pediatr. 2016; 59 (4): 155–64. https://doi.org/10.3345/kjp.2016.59.4.155.

49. Fastenau P.S., Johnson C.S., Perkins S.M., et al. Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology. 2009; 73 (7): 526–34. https://doi.org/10.1212/WNL.0b013e3181b23551.

50. Nicolai J., Ebus S., Biemans D.P., et al. The cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizures. Epilepsia. 2012; 53 (6): 1051–9. https://doi.org/10.1111/j.1528-1167.2012.03491.x.

51. Witt J.A., Alpherts W., Helmstaedter C. Computerized neuropsychological testing in epilepsy: overview of available tools. Seizure. 2013; 22 (6): 416–23. https://doi.org/10.1016/j.seizure.2013.04.004.

52. Witt J.A., Helmstaedter C. Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. J Neurol. 2012; 259 (8): 1727–31. https://doi.org/10.1007/s00415-012-6526-2.

53. Helmstaedter C., Witt J.A. Clinical neuropsychology in epilepsy: theoretical and practical issues. Handb Clin Neurol. 2012; 107: 437–59. https://doi.org/10.1016/B978-0-444-52898-8.00036-7.

54. Whooley M.A., Avins A.L., Miranda J., Browner W.S. Case-finding instruments for depression: Two questions are as good as many. J Gen Intern Med. 1997; 12 (7): 439–45. https://doi.org/10.1046/j.1525-1497.1997.00076.x.

55. Hanaya R., Arita K. The new antiepileptic drugs: their neuropharmacology and clinical indications. Neurol Med Chir (Tokyo). 2016; 56 (5): 205–20. https://doi.org/10.2176/nmc.ra.2015-0344.

56. Trinka E.,Carreno M. Reflections on the use of perampanel in epilepsy – lessons from the clinic and real-world evidence. Eur Neurol Rev. 2017; 12 (1): 17–23. https://doi.org/10.17925/ENR.2017.12.01.17.

57. Gaitatzis A., Carroll K., Majeed A., Sander J.W. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004; 45 (12): 1613–22. https://doi.org/10.1111/j.0013-9580.2004.17504.x.

58. Kanner A.M., Patten A., Malhotra M. Perampanel in patients with a history of psychiatric illness: post hoc analysis of four randomized phase III studies (304, 305, 306, and 335) and their open-label extensions (307 and 335 OLEx) (1850). Presentation. Available at: https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/3201 (accessed December 23, 2020).

59. Sarzhina M.N., Burd S.G., Mironov M.B., Gunchenko M.M., Batysheva T.T. Continuity of specialized care upon transfer of adolescents with epilepsy from a pediatric to adult outpatient service. Epilepsy and Paroxysmal Conditions. 2019; 11 (4): 348–56 (in Russ.). https://doi.org/10.17749/2077-8333.2019.11.4.348-356.

60. Rea R., Traini E., Renna R., et al. Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: a retrospective study. Epilepsy Behav. 2019; 98 (Pt A): 139–44. https://doi.org/10.1016/j.yebeh.2019.07.005.


For citation:


Results of the expert forum on the use of perampanel in adolescents with epilepsy in everyday clinical practice. Epilepsy and paroxysmal conditions. 2020;12(4):248-261. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.054

Views: 122


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)